Table 1

Summary of transplant and clinical characteristics

AnimalMHC disparityPosttransplantation immunosuppressionGraft sourceTNC/kgCD3+/kgCD34+/kgDay of engraftment, donor cells > 25%Day of deathReason for euthanasia
R.1 MHC haploidentical None PBSC 5.5 × 108 1.7 × 108 1.7 × 107 7 7 Severe clinical disability 
R.2 MHC haploidentical None PBSC 7.7 × 108 2.2 × 108 1.8 × 107 6 6 Severe clinical disability 
R.3 MHC haploidentical None BMT 8.6 × 108 4.1 × 107 5.9 × 107 6 22 Progressive clinical disability and weight loss 
R.4 MHC haploidentical CTLA4Ig, anti-CD40 Ab, sirolimus PBSC 1.4 × 109 2.4 × 108 2.1 × 107 8 77 Chronic decrease in activity, and acute clinical decline: CMV and GVHD detected on postmortem analysis 
R.5 MHC haploidentical CTLA4Ig, anti-CD40 Ab, sirolimus BMT + PBSC 9.9 × 108 6.11 × 107 4.5 × 107 5 66 Anorexia and weight loss 
R.6 MHC haploidentical CTLA4Ig, anti-CD40 Ab, sirolimus BMT 1.1 × 109 5.5 × 107 3.3 × 107 5 63 Anorexia and weight loss 
R.7 MHC haploidentical CTLA4Ig, anti-CD40 Ab, sirolimus BMT 8.6 × 108 4.1 × 107 5.9 × 107 12 42 Clinical decline, anorexia, and weight loss; GVHD detected on postmortem analysis 
R.8 MHC haploidentical CTLA4Ig, anti-CD40 Ab, sirolimus BMT 5.2 × 108 1.3 × 108 3.0 × 107 Rejected transplant 64 Anorexia and weight loss 
R.9 MHC haploidentical CTLA4Ig, anti-CD40 Ab, sirolimus BMT 1.3 × 109 2.0 × 107 6.1 × 107 8 20 Planned for timed histopathologic analysis 
R.10 Autologous transplant CTLA4Ig, anti-CD40 Ab, sirolimus PBSC 2.3 × 108 3.2 × 107 1.5 × 107 n/a 35 Planned for histopathologic analysis 
R.11 MHC matched None PBSC 1.1 × 109 1.0 × 108 5.7 × 107 7 26 Severe jaundice 
AnimalMHC disparityPosttransplantation immunosuppressionGraft sourceTNC/kgCD3+/kgCD34+/kgDay of engraftment, donor cells > 25%Day of deathReason for euthanasia
R.1 MHC haploidentical None PBSC 5.5 × 108 1.7 × 108 1.7 × 107 7 7 Severe clinical disability 
R.2 MHC haploidentical None PBSC 7.7 × 108 2.2 × 108 1.8 × 107 6 6 Severe clinical disability 
R.3 MHC haploidentical None BMT 8.6 × 108 4.1 × 107 5.9 × 107 6 22 Progressive clinical disability and weight loss 
R.4 MHC haploidentical CTLA4Ig, anti-CD40 Ab, sirolimus PBSC 1.4 × 109 2.4 × 108 2.1 × 107 8 77 Chronic decrease in activity, and acute clinical decline: CMV and GVHD detected on postmortem analysis 
R.5 MHC haploidentical CTLA4Ig, anti-CD40 Ab, sirolimus BMT + PBSC 9.9 × 108 6.11 × 107 4.5 × 107 5 66 Anorexia and weight loss 
R.6 MHC haploidentical CTLA4Ig, anti-CD40 Ab, sirolimus BMT 1.1 × 109 5.5 × 107 3.3 × 107 5 63 Anorexia and weight loss 
R.7 MHC haploidentical CTLA4Ig, anti-CD40 Ab, sirolimus BMT 8.6 × 108 4.1 × 107 5.9 × 107 12 42 Clinical decline, anorexia, and weight loss; GVHD detected on postmortem analysis 
R.8 MHC haploidentical CTLA4Ig, anti-CD40 Ab, sirolimus BMT 5.2 × 108 1.3 × 108 3.0 × 107 Rejected transplant 64 Anorexia and weight loss 
R.9 MHC haploidentical CTLA4Ig, anti-CD40 Ab, sirolimus BMT 1.3 × 109 2.0 × 107 6.1 × 107 8 20 Planned for timed histopathologic analysis 
R.10 Autologous transplant CTLA4Ig, anti-CD40 Ab, sirolimus PBSC 2.3 × 108 3.2 × 107 1.5 × 107 n/a 35 Planned for histopathologic analysis 
R.11 MHC matched None PBSC 1.1 × 109 1.0 × 108 5.7 × 107 7 26 Severe jaundice 

MHC indicates major histocompatibility complex; TNC, total nucleated cell; PBSC, peripheral blood stem cell; BMT, bone marrow transplantation; Ab, antibody; CMV, cytomegalovirus; and GVHD, graft-versus-host disease.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal